CellSource CoTSE:4880 -2.15%69 PB Ratio is 1.06 as of Jul. 09, 2026, which is 91% below its 10-year median of 12.42. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,226 Biotechnology companies, CellSource Co ranks better than 81.24% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-09), CellSource Co's share price is 円319.00. CellSource Co's Book Value per Share for the quarter that ended in Apr. 2026 was 円301.95. Hence, CellSource Co's PB Ratio of today is 1.06.
Good Sign:
CellSource Co Ltd stock PB Ratio (=1.08) is close to 10-year low of 0.99.
The historical rank and industry rank for CellSource Co's PB Ratio or its related term are showing as below:
TSE:4880'
s PB Ratio Range Over the Past 10 Years
Min: 0.99 Med: 12.42 Max: 59.67
Current: 1.06
During the past 9 years, CellSource Co's highest PB Ratio was 59.67. The lowest was 0.99. And the median was 12.42.
TSE:4880's PB Ratio is ranked better than 81.24% of 1226
companies
in the Biotechnology industry
Industry Median: 2.89
vs TSE:4880: 1.06
During the past 12 months, CellSource Co's average Book Value Per Share Growth Rate was 0.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 24.60% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of CellSource Co was 109.60% per year. The lowest was 14.40% per year. And the median was 35.55% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CellSource Co PB Ratio Related Terms
CellSource Co PB Ratio Historical Data
* Premium members only.
The historical data trend for CellSource Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CellSource Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where CellSource Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
CellSource Co's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CellSource Co (TSE:4880) has a PB Ratio of 1.06 as of Jul. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CellSource Co and its competitors. This is 91% below median its historical median of 12.42. Over the past decade, CellSource Co's PB Ratio has ranged from 0.99 to 59.67. According to the industry distribution chart, CellSource Co ranks #230 out of 1226 companies in the Biotechnology industry, placing it in the top 18.8%.
Is CellSource Co's PB Ratio too high?
CellSource Co's current PB Ratio of 1.06 is 91% below median its 10-year median of 12.42. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 59.67. The Biotechnology industry median PB Ratio is 2.89. CellSource Co's value of 1.06 is 63.3% below this industry median. Based on the distribution chart, CellSource Co ranks #230 out of 1226 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #230 out of 1226 companies for PB Ratio. This places CellSource Co in the top 19% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.89. CellSource Co's value of 1.06 is 63.3% below this benchmark. Historically, CellSource Co's own PB Ratio has ranged from 0.99 to 59.67 over the past decade. While the company's 10-year median is 12.42 vs. the industry median of 2.89, CellSource Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current PB Ratio of 1.06 is 63.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current PB Ratio is 1.06, which is 91% below median its own 10-year median of 12.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current PB Ratio is 1.06, which is 91% below median its 10-year median of 12.42 and 63.3% below the Biotechnology industry median of 2.89. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current PB Ratio is 1.06 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
PB Ratio: 1.06 (91% below median its 10-year median of 12.42)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
Industry Position: 63.3% below the Biotechnology median (#230 of 1226)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
